Craig-Hallum analyst Matt Hewitt lowered the firm’s price target on Repligen to $200 from $207 and keeps a Buy rating on the shares. The firm notes that the bioprocessing market is taking “a breather,” but sees recovery just a couple quarters away.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RGEN:
- Repligen price target raised to $200 from $180 at Stephens
- Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
- Repligen lowers 2023 adjusted EPS view $1.72-$1.80 from $2.35-$2.42
- Repligen reports Q2 adjusted EPS 53c, consensus 47c
- Estee Lauder downgraded, AB InBev upgraded: Wall Street’s top analyst calls